Analyst Ratings For Biomarin Pharmaceutical


Throughout the last three months, 11 analysts have evaluated Biomarin Pharmaceutical BMRN, offering a diverse set of opinions from bullish to bearish.

The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 0 6 5 0 0
Last 30D 0 1 0 0 0
1M Ago 0 3 3 0 0
2M Ago 0 0 0 0 0
3M Ago 0 2 2 0 0

In the assessment of 12-month price targets, analysts unveil insights for Biomarin Pharmaceutical, presenting an average target of $100.73, a high estimate of $113.00, and a low estimate of $85.00. This current average has increased by 1.06% from the previous average price target of $99.67.

Breaking Down Analyst Ratings: A Detailed Examination

A clear picture of Biomarin Pharmaceutical's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Cory Kasimov Evercore ISI Group Announces Outperform $113.00 -
Matthew Harrison Morgan Stanley Lowers Overweight $112.00 $115.00
Whitney Ijem Canaccord Genuity Lowers Hold $89.00 $91.00
David Lebovitz Citigroup Lowers Neutral $91.00 $94.00
George Farmer Scotiabank Raises Sector Perform $85.00 $83.00
Olivia Brayer Cantor Fitzgerald Maintains Overweight $110.00 -
Mohit Bansal Wells Fargo Raises Overweight $110.00 $100.00
Whitney Ijem Canaccord Genuity Maintains Hold $91.00 -
Christopher Raymond Piper Sandler Lowers Overweight $107.00 $115.00
Olivia Brayer Cantor Fitzgerald Maintains Overweight $100.00 -
Luca Issi RBC Capital Maintains Sector Perform $100.00 -

Key Insights:

  • Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Biomarin Pharmaceutical. This information provides a snapshot of how analysts perceive the current state of the company.
  • Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Biomarin Pharmaceutical compared to the broader market.
  • Price Targets: Gaining insights, analysts provide estimates for the future value of Biomarin Pharmaceutical's stock. This comparison reveals trends in analysts' expectations over time.

For valuable insights into Biomarin Pharmaceutical's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

Stay up to date on Biomarin Pharmaceutical analyst ratings.

Delving into Biomarin Pharmaceutical's Background

BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.

Key Indicators: Biomarin Pharmaceutical's Financial Health

Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.

Revenue Growth: Biomarin Pharmaceutical's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 8.79%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: Biomarin Pharmaceutical's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 13.66%, the company may encounter challenges in effective cost control.

Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.77%, the company may need to address challenges in generating satisfactory returns for shareholders.

Return on Assets (ROA): Biomarin Pharmaceutical's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.29%, the company may face hurdles in achieving optimal financial returns.

Debt Management: Biomarin Pharmaceutical's debt-to-equity ratio is below the industry average at 0.22, reflecting a lower dependency on debt financing and a more conservative financial approach.

Analyst Ratings: Simplified

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Price Target
Posted In: Analyst RatingsBZI-AAR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!